Neoadjuvant Immunochemotherapy for Lung Cancer

Lung Cancer Clinical Trial

Official title:

Retrospective Research on Lung Cancer Patients Receiving Neoadjuvant Immunochemotherapy From Zhongshan Hospital Fudan University.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06023797
• Other study ID #: ZS-chest
• Status: Completed
• Start date: January 2017
• Est. completion date: July 2023

Study information

• Verified date: September 2023
• Source: Shanghai Zhongshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: July 2023
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital;

2. At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery;

3. Malignancy was present and confirmed in the pathology before treatment and after surgery;

4. The lung lesion was the primary lesion.

Exclusion Criteria:

1. No lung surgery was performed until 2022.11;

2. No preoperative neoadjuvant therapy was performed or recorded;

3. Neoadjuvant therapy did not include immune drugs;

4. Previous history of malignancy (including surgery and adjuvant therapy);

5. Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• Neoadjuvant immunochemotherapy
Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.

Locations

Country	Name	City	State
China	Zhencong Chen	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	Progression-free defined as status of recurrence of lung cancer	2017-2023
Primary	Overall survival (OS)	Overall defined as the living status, alive or dead	2017-2023